George Bakris

Summary

Publications

  1. doi request reprint Microalbuminuria as a risk predictor in diabetes: the continuing saga
    George L Bakris
    Corresponding author George L Bakris
    Diabetes Care 37:867-75. 2014
  2. doi request reprint CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts
    George L Bakris
    ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL Electronic address
    Am J Med 127:S1. 2014
  3. doi request reprint Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better
    George Bakris
    The University of Chicago Medicine, MC1027, Room P 328A, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Nat Rev Nephrol 9:634-5. 2013
  4. doi request reprint Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease
    George Bakris
    The University of Chicago Medicine, Chicago, IL, USA
    Am J Cardiol 112:255-9. 2013
  5. doi request reprint Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus
    George L Bakris
    Department of Medicine, Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 15:92-100. 2013
  6. doi request reprint Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil
    George L Bakris
    The University of Chicago Medicine, Chicago, IL 60637, USA
    Am J Med 125:1229.e1-1229.e10. 2012
  7. doi request reprint Management of hypertension in the elderly population
    Raymond V Oliva
    FASN, FASH, The University of Chicago Medicine, 5841 S Maryland, MC 1027 Rm P 328, Chicago, Illinois 60637, USA
    J Gerontol A Biol Sci Med Sci 67:1343-51. 2012
  8. doi request reprint Lipid disorders in uremia and dialysis
    George L Bakris
    ASH Comprehensive Hypertension Centre, University of Chicago Medicine, Chicago, Ill 60637, USA
    Contrib Nephrol 178:100-5. 2012
  9. doi request reprint Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker Medical School, Chicago, IL, USA
    J Am Soc Hypertens 6:152-8. 2012
  10. ncbi request reprint Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes
    Rigas G Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 10:156-61. 2012

Collaborators

Detail Information

Publications107 found, 100 shown here

  1. doi request reprint Microalbuminuria as a risk predictor in diabetes: the continuing saga
    George L Bakris
    Corresponding author George L Bakris
    Diabetes Care 37:867-75. 2014
    ....
  2. doi request reprint CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts
    George L Bakris
    ASH Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL Electronic address
    Am J Med 127:S1. 2014
    ....
  3. doi request reprint Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better
    George Bakris
    The University of Chicago Medicine, MC1027, Room P 328A, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Nat Rev Nephrol 9:634-5. 2013
    ..However, a new study suggests that achieving ideal systolic BP targets at the expense of low diastolic BP <70 mmHg is not advantageous for outcomes...
  4. doi request reprint Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease
    George Bakris
    The University of Chicago Medicine, Chicago, IL, USA
    Am J Cardiol 112:255-9. 2013
    ..In conclusion, our findings suggest that the combination of B+A should be preferentially used for older patients with high-risk, stage 2 hypertension. ..
  5. doi request reprint Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus
    George L Bakris
    Department of Medicine, Comprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 15:92-100. 2013
    ..0 mEq/L. Combination aliskiren/valsartan has additive effects on blood pressure reduction and tolerability similar to valsartan in hypertensive/diabetic participants with early-stage (stages 1 and 2) CKD...
  6. doi request reprint Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil
    George L Bakris
    The University of Chicago Medicine, Chicago, IL 60637, USA
    Am J Med 125:1229.e1-1229.e10. 2012
    ..This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates...
  7. doi request reprint Management of hypertension in the elderly population
    Raymond V Oliva
    FASN, FASH, The University of Chicago Medicine, 5841 S Maryland, MC 1027 Rm P 328, Chicago, Illinois 60637, USA
    J Gerontol A Biol Sci Med Sci 67:1343-51. 2012
    ..Diuretics and calcium antagonists are the most efficacious single agents for treatment; however, most patients will require two or more drugs to achieve such goals...
  8. doi request reprint Lipid disorders in uremia and dialysis
    George L Bakris
    ASH Comprehensive Hypertension Centre, University of Chicago Medicine, Chicago, Ill 60637, USA
    Contrib Nephrol 178:100-5. 2012
    ..Given the more 'metabolic syndrome like' profile of lipids in stage 5 CKD adjunctive methods such as fibrates and omega-3 is discussed, however no good data are available in this group on outcomes with these agents...
  9. doi request reprint Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker Medical School, Chicago, IL, USA
    J Am Soc Hypertens 6:152-8. 2012
    ..BAT substantially reduced arterial pressure for most patients participating in the Rheos Pivotal Trial. This blood pressure reduction or goal achievement was maintained over long-term follow-up of 22 to 53 months...
  10. ncbi request reprint Pros and cons of aggressive blood pressure lowering in patients with type 2 diabetes
    Rigas G Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 10:156-61. 2012
    ..This review examines the data for and against aggressive BP lowering in patients with diabetes...
  11. doi request reprint Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial
    George L Bakris
    University of Chicago, Department of Medicine, Hypertensive Disease Unit, Chicago, Ill, USA
    Hypertension 56:824-30. 2010
    ..The results of this trial highlight the importance of ambulatory BP monitoring in the design of hypertension clinical studies...
  12. doi request reprint The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure
    George L Bakris
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 13:81-8. 2011
    ..0 to -0.1; P=.038), while AZL-M 40 mg was noninferior to OLM-M 40 mg. The side effect profiles of both ARBs were similar to placebo. AZL-M is well tolerated and more efficacious at its maximal dose than the highest dose of OLM-M...
  13. doi request reprint Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
    George Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 105:21A-9A. 2010
    ..Therefore, although antihypertensive efficacy is of primary importance in choosing a treatment to provide cardiovascular and renal protection, consideration should be given to the effects of an agent that extend beyond blood pressure...
  14. doi request reprint An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade
    George Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Medical Center, Chicago, IL 60637, USA
    J Cardiovasc Pharmacol 53:379-87. 2009
    ....
  15. doi request reprint Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL 46321, USA
    Kidney Int 75:1272-7. 2009
    ..Clinical research remains to be carried out on the long-term effects of glucosuria and other potential effects of this class of drug. Nonetheless, these compounds represent a very promising approach for the treatment of diabetes...
  16. doi request reprint National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events
    George Bakris
    Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Kidney Int 78:726-36. 2010
    ..This paper summarizes the results of a consensus conference utilizing a patient case to discuss the integrated management of hypertension, kidney disease, dyslipidemia, diabetes, and heart failure across disciplines...
  17. doi request reprint Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Lancet 375:1173-81. 2010
    ..We assessed the effects of these drug combinations on progression of chronic kidney disease...
  18. doi request reprint The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial
    George Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago School of Medicine, Chicago, IL 60637, USA
    J Cardiometab Syndr 3:229-33. 2008
    ..8% of DM patients had blood pressure levels <130/80 mm Hg. ACCOMPLISH will provide valuable guidance on optimizing treatment strategies in hypertensive patients at high cardiovascular risk with and without DM...
  19. doi request reprint ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  20. doi request reprint Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Postgrad Med 121:51-60. 2009
    ..This article also presents an approach to managing increases in creatinine and potassium that should fit comfortably in the hands of primary care clinicians...
  21. doi request reprint Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study
    George L Bakris
    University of Chicago School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 12:678-86. 2010
    ..The tolerability profile of initiating combination therapy was generally comparable to the initiation of treatment with monotherapy...
  22. ncbi request reprint Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study
    George Bakris
    University of Chicago Pritzker School of Medicine, Chicago, IL 60612, USA
    J Cardiometab Syndr 3:18-25. 2008
    ..0 vs 7.2+/-2.3; P<.001). This exploratory study suggests that the impairment in glycemic control seen with use of a thiazide diuretic combined with a RASI can be reversed by switching to a regimen that does not include a diuretic...
  23. ncbi request reprint Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring
    George Bakris
    Department of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 4:26-31. 2002
    ..These data suggest greater efficacy for telmisartan than valsartan in controlling blood pressure throughout the 24-hour dosing interval, including the last 6 hours before dosing, and the two agents were similarly well tolerated...
  24. doi request reprint Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  25. pmc Sociodemographic factors contribute to the depressive affect among African Americans with chronic kidney disease
    Michael J Fischer
    Department of Medicine, Jesse Brown VA Medical Center and University of Illinois Medical Center, Chicago, Illinois, USA
    Kidney Int 77:1010-9. 2010
    ..Sociodemographic factors have especially strong associations with this increased depressive affect. Because this study was conducted in an African-American cohort, its findings may not be generalized to other ethnic groups...
  26. doi request reprint Risk factor assessment for new onset diabetes: literature review
    George Bakris
    Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL 60612, USA
    Diabetes Obes Metab 11:177-87. 2009
    ..Patients with MS may be at lower risk of diabetes when using a FDC calcium channel blocker + angiotensin-converting enzyme inhibitor compared with an angiotensin receptor blocker + TD...
  27. doi request reprint CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004
    Peter A McCullough
    Department of Medicine, Divisions of Cardiology, Nutrition, and Preventive Medicine, William Beaumont Hospital, Royal Oak, MI 48073, USA
    Am J Kidney Dis 51:S38-45. 2008
    ..Chronic kidney disease (CKD) is recognized as an independent cardiovascular disease risk state. The relationship between CKD and cardiovascular disease in volunteer and general populations has not been explored...
  28. ncbi request reprint Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
    Jackson T Wright
    Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106 5014, USA
    JAMA 288:2421-31. 2002
    ..Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD...
  29. pmc Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP)
    Carmen A Peralta
    Department of Medicine, San Francisco VA Medical Center, San Francisco, California, USA
    Arch Intern Med 172:41-7. 2012
    ..Treatment of hypertension is difficult in chronic kidney disease (CKD), and blood pressure goals remain controversial. The association between each blood pressure component and end-stage renal disease (ESRD) risk is less well known...
  30. pmc Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease
    Gabriel Contreras
    Department of Medicine, Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, 1120 NW 14th Street, Suite 360E, Miami, FL 33136, USA
    J Am Soc Nephrol 21:2131-42. 2010
    ..In the M-I group, the corresponding HRs did not vary significantly by cholesterol level. In conclusion, the presence of M-I modifies the risk relationship between cholesterol level and CVD in African Americans with hypertensive CKD...
  31. ncbi request reprint Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker
    George L Bakris
    University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:27-32. 2008
    ..The combination of amlodipine and an angiotensin II receptor blocker is well tolerated, including in patients with stage 2 hypertension and the elderly...
  32. ncbi request reprint Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  33. ncbi request reprint The current state of RAAS blockade in the treatment of hypertension and proteinuria
    Rigas G Kalaitzidis
    Hypertension Diseases Unit, University of Chicago Pritzker School of Medicine, MC1027, Room P 328A, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Curr Cardiol Rep 11:436-42. 2009
    ..Increases in proteinuria, in spite of blood pressure reduction, are associated with faster declines in kidney function regardless of whether RAAS blockers are used...
  34. ncbi request reprint Evaluation and treatment of patients with systemic hypertension
    Jay Garg
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Circulation 105:2458-61. 2002
  35. ncbi request reprint Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers
    George L Bakris
    University of Chicago School of Medicine, Department of Medicine, Hypertensive Diseases Unit, Chicago, Illinois 60637, USA
    Am J Cardiovasc Drugs 7:25-9. 2007
    ....
  36. ncbi request reprint A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...
  37. doi request reprint Efficacy of baroreflex activation therapy for the treatment of resistant hypertension
    Alexandros Briasoulis
    ASH Comprehensive Hypertension Center, Department of Medicine, The University of Chicago Medicine, Chicago, IL 60637, USA
    EuroIntervention 9:R136-9. 2013
    ..Metabolic and humoral mechanisms are also thought to be involved in the development and progression of hypertension-related sympathetic overdrive...
  38. doi request reprint Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial
    John D Bisognano
    Department of Medicine, Cardiology Division, University of Rochester Medical Center, Rochester, New York, USA
    J Am Coll Cardiol 58:765-73. 2011
    ..We sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in patients with resistant hypertension...
  39. doi request reprint Influence of microalbuminuria in achieving blood pressure goals
    Irena Duka
    Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Curr Opin Nephrol Hypertens 17:457-63. 2008
    ....
  40. doi request reprint Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead
    Rigas Kalaitzidis
    Department of Medicine, University of Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 11:636-43. 2009
    ..It remains to be determined whether targeting the underlying inflammatory process can retard or prevent microalbuminuria progression or whether treatment of microalbuminuria can prevent end-stage renal disease or death...
  41. ncbi request reprint The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
    Aram V Chobanian
    Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
    JAMA 289:2560-72. 2003
    ..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
  42. doi request reprint Cardiovascular events during differing hypertension therapies in patients with diabetes
    Michael A Weber
    Department of Medicine, SUNY Downstate College of Medicine, Brooklyn, New York 11203, USA
    J Am Coll Cardiol 56:77-85. 2010
    ..The aim of this study was to determine which combination therapy in patients with hypertension and diabetes most effectively decreases cardiovascular events...
  43. ncbi request reprint Diabetes and chronic kidney disease: tragedy and challenge
    Dave Y Chua
    Department of Preventive Medicine, Rush University Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Blood Purif 22:130-5. 2004
    ....
  44. ncbi request reprint Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals
    George L Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 112:73-4, 77-80, 83-4. 2002
    ..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies...
  45. ncbi request reprint The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension
    Janice Lea
    Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
    Arch Intern Med 165:947-53. 2005
    ..The objective of this study was to relate baseline and early changes in proteinuria and glomerular filtration rate (GFR) to long-term progression of hypertensive nondiabetic kidney disease...
  46. doi request reprint Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP)
    Revekka Babayev
    Department of Medicine, Columbia University Medical Center, New York, NY, USA
    Am J Kidney Dis 61:404-12. 2013
    ..A recent cross-sectional analysis of Kidney Early Evaluation Program (KEEP) participants suggested that obesity is a heterogeneous disease state in African Americans and whites with chronic kidney disease (CKD)...
  47. ncbi request reprint Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women
    Richard A Preston
    Division of Clinical Pharmacology and Pharmacokinetics Clinical Research Center, Department of Medicine, University of Miami School of Medicine, Miami, Florida, USA
    Am J Hypertens 18:797-804. 2005
    ..Because of a significant aldosterone antagonist activity, we studied the effects of DRSP/E2 on serum potassium (K) and blood pressure (BP) in hypertensive postmenopausal women with and without diabetes mellitus...
  48. doi request reprint Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004
    Madhav V Rao
    Department of Medicine, Section of Nephrology, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Kidney Dis 51:S30-7. 2008
    ..Early identification and achievement of blood pressure goals may improve chronic kidney disease outcomes...
  49. doi request reprint Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
    Rigas Kalaitzidis
    Hypertensive Disease Unit, University of Chicago School of Medicine, Chicago, IL 60637, USA
    Postgrad Med 121:77-88. 2009
    ..Whether ARBs can reduce incident diabetes and related cardiovascular outcomes is awaited with the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial...
  50. doi request reprint Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers
    Rigas Kalaitzidis
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Diabetes Obes Metab 11:757-69. 2009
    ..Based on these findings, contemporary treatment guidelines recommend a target SBP/diastolic blood pressure of <130/80 mmHg for patients with diabetes...
  51. ncbi request reprint Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome
    George Bakris
    Department of Preventive Medicine, Rush University Hypertension Center, Chicago, IL 60612, USA
    Diabetes Care 29:2592-7. 2006
    ....
  52. doi request reprint Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Curr Opin Nephrol Hypertens 18:386-91. 2009
    ....
  53. ncbi request reprint Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  54. ncbi request reprint Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 5:202-9. 2003
    ..A fixed-dose combination approach appears as safe as the current conventional approaches...
  55. doi request reprint Fixed-dose combination and chronic kidney disease progression: which is the best?
    Keith A Hopkins
    Hypertensive Diseases Unit, Department of Medicine, The University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Curr Opin Nephrol Hypertens 19:450-5. 2010
    ..Use of combination therapy whether fixed dose or separate pill combinations is becoming more prevalent. Physicians are not routinely trained in using combinations of different antihypertensive medicines...
  56. ncbi request reprint Protecting renal function in the hypertensive patient: clinical guidelines
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:112S-119S. 2005
    ..This is achieved optimally by using agents that block the renin-angiotensin system in concert with other agents that reduce proteinuria and BP...
  57. pmc Slowing nephropathy progression: focus on proteinuria reduction
    George L Bakris
    Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Clin J Am Soc Nephrol 3:S3-10. 2008
    ..These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits...
  58. ncbi request reprint Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics
    Munavvar Izhar
    Rush Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Hypertension 43:573-7. 2004
    ..Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency...
  59. ncbi request reprint Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans
    Nicholas Kaperonis
    Department of Preventive Medicine, Rush University Hypertension Clinical Research Center, Rush Medical College, Chicago, Illinois 60612, USA
    Curr Opin Nephrol Hypertens 12:79-84. 2003
    ....
  60. doi request reprint Pathogenesis and clinical physiology of hypertension
    Mukesh Singh
    University of Chicago Pritzker School of Medicine, IL 60637, USA
    Cardiol Clin 28:545-59. 2010
    ..A unifying pathway for the development of hypertension and the practical implications for the prevention and control of hypertension are discussed...
  61. ncbi request reprint How to adjust ACE inhibitors and ARBs in diabetes?
    George Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Center, Rush Presbyterian St Luke s Medical Center, Chicago, USA
    Postgrad Med 115:9-10. 2004
  62. doi request reprint Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP)
    Rigas Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Am J Kidney Dis 53:S22-31. 2009
    ..Chronic kidney disease (CKD) is a worldwide public health problem. Systolic blood pressure as an associated feature of CKD has not been fully explored in community volunteer and nationally representative samples of the US population...
  63. doi request reprint The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    J Hypertens 27:666-9. 2009
    ..Therefore, treatment of hypertension has become the most important intervention in the management of all forms of CKD. For this reason, the forthcoming World Kidney Day on 12 March 2009 will emphasize the role of hypertension...
  64. ncbi request reprint Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)
    Garabed Eknoyan
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Am J Kidney Dis 42:617-22. 2003
  65. ncbi request reprint Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
    Arch Intern Med 163:1555-65. 2003
    ..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death...
  66. ncbi request reprint Clinical importance of microalbuminuria in diabetes and hypertension
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Hypertens Rep 6:352-6. 2004
    ..Further lowering of albuminuria may be achieved by adding verapamil, diltiazem, or an ARB to an ACE inhibitor...
  67. ncbi request reprint Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  68. ncbi request reprint Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk
    Rigas G Kalaitzidis
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
    Curr Vasc Pharmacol 8:604-11. 2010
    ..Thus, concomitant evaluation of both biomarkers eGFR and albuminuria is recommended to assess kidney function and CV risk thoroughly...
  69. ncbi request reprint Antihypertensive therapy in the presence of proteinuria
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
    Am J Kidney Dis 49:12-26. 2007
    ....
  70. ncbi request reprint Who should be treated with combination therapy as initial treatment for hypertension?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:21-8. 2003
    ....
  71. ncbi request reprint Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient?
    George L Bakris
    University of Chicago, IL, USA
    Prev Cardiol 11:42-9. 2008
    ..The authors maintained full control of the discussion and the resulting content of this article...
  72. doi request reprint Hypertension goals in advanced-stage kidney disease
    Keith Hopkins
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin J Am Soc Nephrol 4:S92-4. 2009
    ..Aggressive volume control seems key to maintaining good BP control. Once a valid time and measure for BP is agreed on, a clinical outcome trial is needed to test its utility...
  73. doi request reprint Using an established telehealth model to train urban primary care providers on hypertension management
    Christopher Masi
    University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 14:45-50. 2012
    ..68 [SD=0.94] to 5.41 [SD=0.89], P<.01) but not among controls (5.28 [SD=0.43] to 5.62 [SD=0.67], P=.64). This model holds promise for enhancing hypertension care provided by urban FQHC providers...
  74. ncbi request reprint When to refer patients to a nephrologist?
    George Bakris
    Departments of Preventive Medicine and Internal Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, USA
    Postgrad Med 113:11. 2003
  75. ncbi request reprint Is ethnicity a factor in choice of antihypertensive drug?
    George Bakris
    Department of Preventive Medicine, Rush Hypertension Clinical Research Center, Rush University Medical Center, Chicago, USA
    Postgrad Med 117:40. 2005
  76. ncbi request reprint Lessons learned from recent hypertension trials about kidney disease
    Nitin Khosla
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    Clin J Am Soc Nephrol 1:229-35. 2006
  77. ncbi request reprint Achieving blood pressure goals: is fixed-dose combination therapy the answer?
    George L Bakris
    Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 5:2-3. 2003
  78. ncbi request reprint Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction
    George L Bakris
    Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
    Curr Diab Rep 2:258-62. 2002
    ..In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke...
  79. doi request reprint Dual RAAS blockade is desirable in kidney disease: con
    George L Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Kidney Int 78:546-9. 2010
    ..In all cases other than advanced proteinuric nephropathy, there is no evidence of any positive CKD outcome with dual RAAS blockade. Thus, dual RAAS blockade cannot be recommended for all CKD patients...
  80. ncbi request reprint Blood pressure control and nephroprotection in diabetes
    Kevin Abbott
    Walter Reed Army Hospital, Department of Medicine, Division of Nephrology, Bethesda, Maryland, USA
    J Clin Pharmacol 44:431-8. 2004
    ..Physicians need to work harder and educate patients on the importance of achieving these lower blood pressure guidelines...
  81. ncbi request reprint The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols
    George L Bakris
    Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
    Postgrad Med 113:35-40, 43-4, 50. 2003
    ..He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes...
  82. ncbi request reprint The role of calcium antagonists in chronic kidney disease
    Casey N Gashti
    Rush University Hypertension Clinical Research Centre, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Centre, Chicago, Illinois 60612, USA
    Curr Opin Nephrol Hypertens 13:155-61. 2004
    ..To review goals of antihypertensive treatment in chronic kidney disease in the context of what role calcium antagonists play toward reducing progression of kidney disease...
  83. ncbi request reprint Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study
    Jay P Garg
    Division of Nephrology, Department of Medicine, University of California San Francisco, USA
    Am J Nephrol 25:393-9. 2005
    ..Because angiotensin II may have adverse effects on the arterial wall, we hypothesized that an angiotensin receptor blocker (ARB) would improve arterial compliance as compared with placebo in subjects with CKD...
  84. ncbi request reprint Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  85. ncbi request reprint Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study
    Henry R Black
    New York University School of Medicine, New York, NY 10016, USA
    J Clin Hypertens (Greenwich) 9:760-9. 2007
    ....
  86. doi request reprint The kidney, hypertension, and remaining challenges
    Nitin Khosla
    Department of Medicine, Section of Nephrology and Hypertension, University of California at San Diego, San Diego, CA, USA
    Med Clin North Am 93:697-715, Table of Contents. 2009
    ..Second, the appropriate initiation of fixed-dose combination therapy to achieve blood-pressure goals needs to be clarified. Finally, the subgroup of patients with kidney disease needs more aggressive blood pressure lowering...
  87. ncbi request reprint Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
    George Bakris
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    J Hypertens 20:2257-67. 2002
    ..DESIGN This was a 1-year, prospective, randomized, double-blind, placebo-controlled, multicenter trial of orlistat plus diet versus placebo plus diet in obese hypertensives...
  88. ncbi request reprint A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes
    George Bakris
    Department of Preventive Medicine, Rush Hypertension Clinical Research Center, Chicago, Illinois, USA
    Am J Hypertens 15:53-7. 2002
    ....
  89. doi request reprint Cardiovascular protection for all individuals at high risk: evidence-based best practice
    George Bakris
    Department of Medicine, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Clin Res Cardiol 97:713-25. 2008
    ....
  90. ncbi request reprint Preventing hypertensive kidney disease: the critical role of combination therapy
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Hypertens 18:93S-94S. 2005
  91. ncbi request reprint Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
    Nitin Khosla
    Department of Preventive Medicine, Rush Hypertension Clinical Research Center, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:354-6. 2005
  92. ncbi request reprint Implications of albuminuria on kidney disease progression
    George L Bakris
    Rush University Hypertension Center, Rush University Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 6:18-22. 2004
    ..Use of an angiotensin receptor blocker added to an angiotensin-converting enzyme inhibitor or vice versa can further lower albuminuria by an additional 30%-40%, which is not true of the additional lowering of BP...
  93. ncbi request reprint The importance of blood pressure control in the patient with diabetes
    George L Bakris
    Departments of Preventative and Internal Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    Am J Med 116:30S-38S. 2004
    ..The new beta-blockers may play an important role in achieving blood pressure goals...
  94. ncbi request reprint Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria
    George L Bakris
    Rush University Medical Center, Chicago, Illinois 60612, USA
    J Hypertens 24:2047-55. 2006
    ..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control...
  95. ncbi request reprint Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile
    George L Bakris
    Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Am J Cardiol 98:46L-52L. 2006
    ..These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors...
  96. ncbi request reprint Microalbuminuria: what is it? Why is it important? What should be done about it? An update
    Atul Chugh
    Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Pritzker School of Medicine, IL 60637, USA
    J Clin Hypertens (Greenwich) 9:196-200. 2007
    ..The National Kidney Foundation recommends that blood pressure levels be maintained at or below 130/80 mm Hg in anyone with diabetes or kidney disease...
  97. ncbi request reprint A comparative evaluation of various methods for microalbuminuria screening
    Pantelis A Sarafidis
    Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    Am J Nephrol 28:324-9. 2008
    ..We evaluated a new quantitative office-based method to assess urinary albumin excretion (UAE) and compared it to other established methods...
  98. ncbi request reprint Comparative efficacy of two different beta-blockers on 24-hour blood pressure control
    Pantelis Sarafidis
    Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Chicago, IL, USA
    J Clin Hypertens (Greenwich) 10:112-8. 2008
    ..It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-hour period...
  99. doi request reprint Predictors of hyperkalemia risk following hypertension control with aldosterone blockade
    Nitin Khosla
    Department of Medicine, Section of Nephrology and Hypertension, University of California at San Diego, San Diego, CA, USA
    Am J Nephrol 30:418-24. 2009
    ..This study assesses the risk factors for hyperkalemia in patients with chronic kidney disease (CKD) and resistant hypertension whose blood pressure (BP) is reduced to a guideline goal...
  100. doi request reprint Effects of angiotensin II receptor blockers on diabetic nephropathy
    Rigas Kalaitzidis
    Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
    J Hypertens Suppl 27:S15-21. 2009
    ....
  101. pmc Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors
    Michael L Maitland
    Department of Medicine, University of Chicago Medical Center, 5841Chicago, IL 60637, USA
    J Natl Cancer Inst 102:596-604. 2010
    ..Proper agent selection, dosing, and scheduling of follow-up should enable maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP...